Abstract

BackgroundMastitis and accompanying pain have been associated with the cessation of breastfeeding. Mastitis is an inflammatory condition of the breast and may be a result of decreased immunity and a lowered resistance to infection. Mastitis affects up to one in five breastfeeding women with most episodes occurring in the first 6–8 weeks postpartum. Antibiotics are often used in the treatment of mastitis, but have not been popular or proven effective as a preventative agent. The WHO has highlighted significant concerns relating to adverse harms of antibiotic use with the production of antibiotic-resistant strains of disease organisms. Increasing research suggests that specific probiotic bacteria possess significant anti-inflammatory properties and supports their potential use as immunomodulatory agents. While animal studies have shown promising results in the use of probiotics for preventing mastitis, their use in human trials has had limited investigation. The aim of this study is to evaluate the effectiveness of oral probiotics for the prevention of mastitis in breastfeeding women.MethodsAPProve (CAn Probiotics ImProve Breastfeeding Outcomes?) is a double-blind randomised controlled trial designed to assess outcomes between breastfeeding women ingesting a probiotic versus a placebo daily for 8 weeks following birth. A total of 600 women (300 to each arm) who intend to breastfeed will be randomised after the birth of a term, healthy infant. Daily and weekly surveys for 8 weeks and follow-up surveys at 2, 6 and 12 months after birth will assess the primary outcome of mastitis in the first 8 weeks following birth as well as secondary maternal outcomes of breastfeeding duration (total/partial), antibiotic use, maternal health and well-being, and treatment compliance; and infant outcomes including gastroenteritis, infant health and well-being and growth and development. The acceptability and compliance using a novel mobile phone application system will also be evaluated.DiscussionThere is an urgent need to explore safe and effective alternatives for preventing mastitis in breastfeeding women. This trial seeks to provide evidence for such an alternative in the form of probiotics, which may also increase breastfeeding duration, providing long-term health, cognitive and developmental benefits for children. Decreased antibiotic usage also benefits the community and health system.Trial registrationAustralian New Zealand Clinical Trials Registry: ACTRN12615000923561.Date of registration: 4th September, 2015, retrospectively registered.

Highlights

  • Mastitis and accompanying pain have been associated with the cessation of breastfeeding

  • Given the positive benefits of breastfeeding, it is of concern that the 2010 Australian Institute of Health and Welfare (AIHW) National Health Survey reported less than 15% of women exclusively breastfeeding at 5 months of age, despite a 96% initiation rate at birth [4]

  • These findings suggest that more resources and research are required to identify and treat the underlying causes of breastfeeding cessation in order to extend the overall duration and improve long term maternal and child health outcomes

Read more

Summary

Introduction

Mastitis and accompanying pain have been associated with the cessation of breastfeeding. Given the positive benefits of breastfeeding, it is of concern that the 2010 Australian Institute of Health and Welfare (AIHW) National Health Survey reported less than 15% of women exclusively breastfeeding at 5 months of age, despite a 96% initiation rate at birth [4] These findings suggest that more resources and research are required to identify and treat the underlying causes of breastfeeding cessation in order to extend the overall duration and improve long term maternal and child health outcomes. The World Health Organisation (WHO) defines mastitis as an inflammatory condition of the breast, which may or may not be accompanied by infection [8] It occurs in 15–21% of breastfeeding mothers in Australia [9,10,11]. Almost one-third of women experience a recurrent episode [13,14,15], and up to 3% of women with mastitis develop a breast abscess, often necessitating hospitalisation [16, 17]

Objectives
Methods
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call